Two more drug-making giants, Abbvie and Genentech, will start selling popular medications on the White House's discounted ...
The US Food and Drug Administration (FDA) today approved a new autoinjection option for adalimumab-adbm (Cyltezo), a biosimilar to AbbVie's adalimumab (Humira), ahead of Cyltezo's commercial launch on ...
FILE - Packaging for AbbVie's drug, Humira. Patients who take the autoimmune disease treatment can get some price relief when lower-cost, biosimilar versions are included on health plan formularies.
Please provide your email address to receive an email when new articles are posted on . Quallent will offer both low- and high-concentration citrate-free adalimumab-adbm. The existing biosimilar ...
Boehringer Ingelheim announced an agreement with Quallent Pharmaceuticals, a private label pharmaceutical distributor, to help expand patient access to citrate-free adalimumab-adbm, Boehringer’s ...
June 1 (Reuters) - Coherus BioSciences Inc (CHRS.O), opens new tab said on Thursday it plans to launch a biosimilar of AbbVie Inc's (ABBV.N), opens new tab Humira in July at a list price of $995 per ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results